Canakinumab (Anti-IL-1b) is a recombinant human anti-IL-1β monoclonal antibody targeting IL-1β and neutralizing IL-1β signaling. It can be used in treatment of disorders of autoimmune origin like familial mediterranean fever, mevalonate kinase deficiency, tumor necrosis factor receptor-associated periodic syndrome (TRAPS). MW :145.5 KD.